CannabisNewsWire Editorial Coverage: Relatively insulated from economic cycles, the innovation of today’s biotech companies puts them in a position to potentially deliver outsized returns regardless of overall conditions. Medicinal cannabis, a key sector in this industry, is currently driving the largest returns, and it is on pace to exceed US$50 billion in revenues by 2025. As more investors are noticing, positive news continues to flow into the sector in terms of new drug applications, product approvals and pipeline updates. For InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), a preclinical-stage biopharmaceutical company at the vanguard of cannabinoid-based bio-pharmacology, market awareness of the company’s drug development pipeline and biosynthesis technology has led to gains of more than 400% over the last year. This level of activity places InMed, currently valued at $100 million, among the ranks of larger cannabis biotechs like GW Pharma (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF).
Backed by mounting scientific data on the curative effects of CBDs, specialty biotech companies have the opportunity to capitalize on the explosive growth expected in the cannabis-derived pharmaceutical market. The discovery of the human endocannabinoid system dramatically changed both the understanding and the vast potential of cannabinoid therapeutics, and thus has increased acceptance and awareness of the potential of cannabinoids to affect a much broader range of physiological functions than previously considered. With a tsunami of innovation, cannabinoid pharmaceutical companies now research, identify and develop new drug candidates to create unique therapeutics to treat multiple maladies and unmet medical needs.
Read the full article